A PHASE Ib, OPEN LABEL, DOSE ESCALATION STUDY OF THE SAFETY AND PHARMACOLOGY OF GDC-0941 IN COMBINATION WITH ERLOTINIB IN PATIENTS WITH ADVANCED SOLID TUMORS

Objective

Clinical trial of investigational drug GDC-0941 and erlotinib given by mouth.

IRB Protocol Number

09-0403

Principal Investigator(s)

STEPHEN LEONG

Cancer Trials

• All Cancers

Sponsor(s)

Genentech, Inc.

Contact

SHARON HECKER at 720-848-0667
or SHARON.HECKER@ucdenver.edu

Eligibility and Other Participant Information

What To Expect : A screening period to determine eligibility. A treatment period that can last up to one year as long as you are responding well to the study drug. A follow up period will consist of a clinic visit 30 days after you stop taking the study drug. // Eligibility criteria include but are not limited to 18 years or older with advanced solid tumor(s).